Filtered By:
Drug: Dexamethasone
This page shows you your search results in order of relevance. This is page number 14.
Order by Relevance | Date
Total 8422 results found since Jan 2013.
Assessment of the efficacy of ofatumumab in patients with chronic lymphocytic leukaemia treated in the Department of Haematooncology and Bone Marrow Transplantation of the Medical University in Lublin - Prelimary results.
CONCLUSIONS: Ofatumumab may be a new and safe therapeutic option for patients with CLL after a few lines of treatment.
PMID: 29575875 [PubMed - in process]
Source: Annals of Agricultural and Environmental Medicine : AAEM - March 14, 2018 Category: Environmental Health Authors: Wąsik-Szczepanek E, Szymczyk A, Kowal M, Nogalski A, Hus M Tags: Ann Agric Environ Med Source Type: research
Treatment Sequencing in Patients with Relapsed/Refractory Multiple Myeloma after Daratumumab Treatment: Real-World Findings from a Pooled Data Analysis of Preamble and the Mckesson Electronic Medical Record Database
Conclusions: In this analysis, pts with RRMM after failure of dara switched to a variety of regimens. The majority received regimens containing IMiDs and PIs despite having been exposed to those agents in the past. Elo-based regimens were received by 21% of pts with RRMM after failure of dara, with most pts receiving elo in combination with len, and were associated with a higher DoT (151 d) after dara than other regimens in this analysis. Elo plus Pd may therefore be an option after dara, as pom is used less frequently in earlier LoTs.Study support: Bristol-Myers Squibb (BMS). Medical writing: K Tran, Caudex, funded by BMS...
Source: Blood - November 21, 2018 Category: Hematology Authors: Vij, R., Chen, C., Yasenchak, C. A., Davis, C., Kuter, D. J. Tags: 653. Myeloma: Therapy, excluding Transplantation: Poster II Source Type: research
Medical Decision Analysis: Choosing Second Line Treatment in Adults with Immune Thrombocytopenia (ITP)
Conclusion: In the USA, TDS has the longest lifespan at a cost of approximately $130,000 per additional year of life. In Europe the cost for the additional year of life is < $20,000. If USA costs were as low as they are in Europe, there would be no compelling economic reason to select one of the specific second line therapies so treatment could be individualized according to physician and patient preference.DisclosuresBussel: Amgen Inc.: Consultancy, Research Funding; Uptodate: Honoraria; Momenta: Consultancy; Protalex: Consultancy; Prophylix: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Rigel...
Source: Blood - November 21, 2018 Category: Hematology Authors: Skopec, B., James, H. P., Bussel, J. B. Tags: 311. Disorders of Platelet Number or Function Source Type: research
Medical Interventions for Chylothorax and their Impacts on Need for Surgical Intervention and Admission Characteristics: A Multicenter, Retrospective Insight
AbstractThe incidence of chylothorax is reported from 1 –9% in pediatric patients undergoing congenital heart surgery. Effective evidenced-based practice is limited for the management of post-operative chylothorax in the pediatric cardiac intensive care unit. The study characterizes the population of pediatric patients with cardiac surgery and chylotho rax who eventually require pleurodesis and/or thoracic duct ligation; it also establishes objective data on the impact of various medical interventions. Data were obtained from the Pediatric Health Information System database from 2004–2015. Inclusion criteria for admiss...
Source: Mammalian Genome - January 4, 2021 Category: Genetics & Stem Cells Source Type: research
Mycoplasma affects baseline gene expression and the response to glucocorticoids in vocal fold fibroblasts
Conclusion. Variability of mycoplasma presence across culture conditions and differential responses to exogenous stimuli as a function of mycoplasma presence are potentially problematic for the translation of in vitro experimentation in the upper aerodigestive tract. It remains unclear if these findings represent contamination or the baseline state of this specialized tissue.PMID:34038343 | DOI:10.1099/jmm.0.001362
Source: Journal of Medical Microbiology - May 26, 2021 Category: Microbiology Authors: Carina Doyle Ryosuke Nakamura Renjie Bing Bernard Rousseau Ryan C Branski Source Type: research
Dexamethasone for treating SARS-CoV-2 infection: a systematic review and meta-analysis
CONCLUSIONS: This study suggests that dexamethasone may significantly improve the outcome among hospitalized patients with SARS-CoV-2 infection and associated severe respiratory complications. -Further studies need to consider both dose-dependent administration and outcomes in early and later stages of the disease.PROSPERO PLATFORM: CRD42021229825.PMID:34644768 | DOI:10.1590/1516-3180.2021.0120.R1.30062021
Source: Sao Paulo Medical Journal - October 13, 2021 Category: General Medicine Authors: Lirane Elize Defante Ferreto Durcelina Schiavoni Bortoloti Paulo Cezar Nunes Fortes Franciele Follador Gisele Arruda Jo ão Paulo Ximenez Guilherme Welter Wendt Source Type: research
Activation of CpG-ODN-Induced TLR9 Signaling Inhibited by Interleukin-37 in U937 Human Macrophages
CONCLUSION: IL-37 inhibits CpG-ODN-mediated inflammatory responses through regulation of a TRAF6-NF-κB pathway in human macrophages.PMID:34672136 | DOI:10.3349/ymj.2021.62.11.1023
Source: Yonsei Medical Journal - October 21, 2021 Category: Universities & Medical Training Authors: Seong-Kyu Kim Jung-Yoon Choe Ki-Yeun Park Source Type: research
Dexamethasone for treating SARS-CoV-2 infection: a systematic review and meta-analysis
CONCLUSIONS: This study suggests that dexamethasone may significantly improve the outcome among hospitalized patients with SARS-CoV-2 infection and associated severe respiratory complications. -Further studies need to consider both dose-dependent administration and outcomes in early and later stages of the disease.PROSPERO PLATFORM: CRD42021229825.PMID:34644768 | DOI:10.1590/1516-3180.2021.0120.R1.30062021
Source: Sao Paulo Medical Journal - October 13, 2021 Category: General Medicine Authors: Lirane Elize Defante Ferreto Durcelina Schiavoni Bortoloti Paulo Cezar Nunes Fortes Franciele Follador Gisele Arruda Jo ão Paulo Ximenez Guilherme Welter Wendt Source Type: research
